Nkarta, Inc. (NKTX)
2.92
+0.13
(+4.66%)
USD |
NASDAQ |
Sep 04, 16:00
2.91
-0.01
(-0.34%)
After-Hours: 20:00
Nkarta Research and Development Expense (Quarterly) : 26.31M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 26.31M |
| March 31, 2026 | 22.65M |
| December 31, 2025 | 23.02M |
| September 30, 2025 | 17.89M |
| June 30, 2025 | 18.45M |
| March 31, 2025 | 21.87M |
| December 31, 2024 | 20.84M |
| September 30, 2024 | 22.90M |
| June 30, 2024 | 20.87M |
| March 31, 2024 | 22.98M |
| December 31, 2023 | 21.07M |
| September 30, 2023 | 20.21M |
| June 30, 2023 | 24.28M |
| March 31, 2023 | 25.34M |
| December 31, 2022 | 26.12M |
| Date | Value |
|---|---|
| September 30, 2022 | 22.77M |
| June 30, 2022 | 20.42M |
| March 31, 2022 | 18.96M |
| December 31, 2021 | 17.30M |
| September 30, 2021 | 16.08M |
| June 30, 2021 | 15.59M |
| March 31, 2021 | 13.24M |
| December 31, 2020 | 10.99M |
| September 30, 2020 | 9.606M |
| June 30, 2020 | 7.762M |
| March 31, 2020 | 7.119M |
| December 31, 2019 | 6.553M |
| September 30, 2019 | 4.513M |
| June 30, 2019 | 3.321M |
| March 31, 2019 | 2.223M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Ironwood Pharmaceuticals, Inc. | 21.96M |
| Theriva Biologics, Inc. | 1.268M |
| Yarrow Bioscience, Inc. | 0.788M |
| Unicycive Therapeutics, Inc. | 2.788M |
| OnKure Therapeutics, Inc. | 12.51M |